vs
LCNB CORP（LCNB）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是LCNB CORP的1.3倍（$30.3M vs $23.9M），LCNB CORP净利率更高（23.7% vs -221.3%，领先245.1%），REGENXBIO Inc.同比增速更快（43.0% vs 5.1%），LCNB CORP自由现金流更多（$33.4M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 15.7%）
LCNB集团是总部位于美国的金融控股公司，通过旗下附属国民银行开展业务，主要为俄亥俄州区域市场的个人消费者、中小企业及本地社区机构提供零售与商业银行产品、财富管理及保险相关服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
LCNB vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.3倍
$23.9M
营收增速更快
RGNX
高出37.9%
5.1%
净利率更高
LCNB
高出245.1%
-221.3%
自由现金流更多
LCNB
多$86.2M
$-52.8M
两年增速更快
RGNX
近两年复合增速
15.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.9M | $30.3M |
| 净利润 | $5.7M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 29.2% | -190.0% |
| 净利率 | 23.7% | -221.3% |
| 营收同比 | 5.1% | 43.0% |
| 净利润同比 | -7.6% | -31.2% |
| 每股收益（稀释后） | $0.40 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LCNBRGNX
| Q4 25 | $23.9M | $30.3M | ||
| Q3 25 | $23.8M | $29.7M | ||
| Q2 25 | $22.8M | $21.4M | ||
| Q1 25 | $21.5M | $89.0M | ||
| Q4 24 | $22.7M | $21.2M | ||
| Q3 24 | $21.4M | $24.2M | ||
| Q2 24 | $19.3M | $22.3M | ||
| Q1 24 | $17.8M | $15.6M |
净利润LCNBRGNX
| Q4 25 | $5.7M | $-67.1M | ||
| Q3 25 | $6.9M | $-61.9M | ||
| Q2 25 | $5.9M | $-70.9M | ||
| Q1 25 | $4.6M | $6.1M | ||
| Q4 24 | $6.1M | $-51.2M | ||
| Q3 24 | $4.5M | $-59.6M | ||
| Q2 24 | $925.0K | $-53.0M | ||
| Q1 24 | $1.9M | $-63.3M |
毛利率LCNBRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率LCNBRGNX
| Q4 25 | 29.2% | -190.0% | ||
| Q3 25 | 35.6% | -176.3% | ||
| Q2 25 | 31.6% | -296.3% | ||
| Q1 25 | 25.6% | 13.6% | ||
| Q4 24 | 32.9% | -242.1% | ||
| Q3 24 | 24.9% | -256.6% | ||
| Q2 24 | 4.9% | -251.3% | ||
| Q1 24 | 12.5% | -408.8% |
净利率LCNBRGNX
| Q4 25 | 23.7% | -221.3% | ||
| Q3 25 | 29.1% | -208.3% | ||
| Q2 25 | 26.0% | -331.8% | ||
| Q1 25 | 21.4% | 6.8% | ||
| Q4 24 | 27.0% | -241.3% | ||
| Q3 24 | 21.2% | -246.3% | ||
| Q2 24 | 4.8% | -237.7% | ||
| Q1 24 | 10.7% | -405.4% |
每股收益（稀释后）LCNBRGNX
| Q4 25 | $0.40 | $-1.30 | ||
| Q3 25 | $0.49 | $-1.20 | ||
| Q2 25 | $0.41 | $-1.38 | ||
| Q1 25 | $0.33 | $0.12 | ||
| Q4 24 | $0.44 | $-0.99 | ||
| Q3 24 | $0.31 | $-1.17 | ||
| Q2 24 | $0.07 | $-1.05 | ||
| Q1 24 | $0.15 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $21.6M | $230.1M |
| 总债务越低越好 | $104.4M | — |
| 股东权益账面价值 | $273.9M | $102.7M |
| 总资产 | $2.2B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.38× | — |
8季度趋势，按日历期对齐
现金及短期投资LCNBRGNX
| Q4 25 | $21.6M | $230.1M | ||
| Q3 25 | $35.9M | $274.2M | ||
| Q2 25 | $49.8M | $323.3M | ||
| Q1 25 | $37.7M | $267.9M | ||
| Q4 24 | $35.7M | $234.7M | ||
| Q3 24 | $39.4M | $255.5M | ||
| Q2 24 | $34.9M | $290.4M | ||
| Q1 24 | $33.0M | $338.7M |
总债务LCNBRGNX
| Q4 25 | $104.4M | — | ||
| Q3 25 | $104.7M | — | ||
| Q2 25 | $105.0M | — | ||
| Q1 25 | $104.6M | — | ||
| Q4 24 | $155.2M | — | ||
| Q3 24 | $155.7M | — | ||
| Q2 24 | $162.2M | — | ||
| Q1 24 | $162.6M | — |
股东权益LCNBRGNX
| Q4 25 | $273.9M | $102.7M | ||
| Q3 25 | $269.9M | $161.5M | ||
| Q2 25 | $263.5M | $213.7M | ||
| Q1 25 | $258.7M | $274.2M | ||
| Q4 24 | $253.0M | $259.7M | ||
| Q3 24 | $253.2M | $301.4M | ||
| Q2 24 | $245.2M | $348.3M | ||
| Q1 24 | $233.7M | $390.7M |
总资产LCNBRGNX
| Q4 25 | $2.2B | $453.0M | ||
| Q3 25 | $2.2B | $525.2M | ||
| Q2 25 | $2.3B | $581.0M | ||
| Q1 25 | $2.3B | $490.9M | ||
| Q4 24 | $2.3B | $466.0M | ||
| Q3 24 | $2.3B | $519.1M | ||
| Q2 24 | $2.4B | $569.4M | ||
| Q1 24 | $2.3B | $629.2M |
负债/权益比LCNBRGNX
| Q4 25 | 0.38× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | 0.40× | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.66× | — | ||
| Q1 24 | 0.70× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $34.4M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $33.4M | $-52.8M |
| 自由现金流率自由现金流/营收 | 140.2% | -174.0% |
| 资本支出强度资本支出/营收 | 4.0% | 1.7% |
| 现金转化率经营现金流/净利润 | 6.08× | — |
| 过去12个月自由现金流最近4个季度 | $54.5M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流LCNBRGNX
| Q4 25 | $34.4M | $-52.3M | ||
| Q3 25 | $14.0M | $-56.0M | ||
| Q2 25 | $5.5M | $-49.3M | ||
| Q1 25 | $2.2M | $33.6M | ||
| Q4 24 | $93.2M | $-31.6M | ||
| Q3 24 | $11.9M | $-40.5M | ||
| Q2 24 | $54.9M | $-45.5M | ||
| Q1 24 | $-11.9M | $-55.5M |
自由现金流LCNBRGNX
| Q4 25 | $33.4M | $-52.8M | ||
| Q3 25 | $13.7M | $-56.5M | ||
| Q2 25 | $5.2M | $-49.7M | ||
| Q1 25 | $2.1M | $32.6M | ||
| Q4 24 | $89.4M | $-32.7M | ||
| Q3 24 | $10.5M | $-40.9M | ||
| Q2 24 | $53.8M | $-46.0M | ||
| Q1 24 | $-12.8M | $-56.0M |
自由现金流率LCNBRGNX
| Q4 25 | 140.2% | -174.0% | ||
| Q3 25 | 57.4% | -189.9% | ||
| Q2 25 | 23.0% | -232.8% | ||
| Q1 25 | 10.0% | 36.6% | ||
| Q4 24 | 394.0% | -154.2% | ||
| Q3 24 | 49.0% | -168.9% | ||
| Q2 24 | 278.6% | -206.2% | ||
| Q1 24 | -71.8% | -358.5% |
资本支出强度LCNBRGNX
| Q4 25 | 4.0% | 1.7% | ||
| Q3 25 | 1.3% | 1.7% | ||
| Q2 25 | 1.0% | 1.8% | ||
| Q1 25 | 0.3% | 1.2% | ||
| Q4 24 | 16.7% | 5.1% | ||
| Q3 24 | 6.7% | 1.3% | ||
| Q2 24 | 5.9% | 2.1% | ||
| Q1 24 | 4.8% | 3.6% |
现金转化率LCNBRGNX
| Q4 25 | 6.08× | — | ||
| Q3 25 | 2.02× | — | ||
| Q2 25 | 0.92× | — | ||
| Q1 25 | 0.48× | 5.53× | ||
| Q4 24 | 15.23× | — | ||
| Q3 24 | 2.63× | — | ||
| Q2 24 | 59.35× | — | ||
| Q1 24 | -6.24× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LCNB
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
